Skip to content, Open navigation or Skip to contact information.

Copyright © Inderes 2011 - present. All rights reserved.
Latest
Markets
Stock Comparison
Calendar
Research
Articles
inderesTV
Portfolio
Forum
Customer Companies
Settings
Copyright © Inderes 2011 - present. All rights reserved.
​
​
Log in to receive notifications.
Claus Thestrup portrait

Claus Thestrup

Analyst

Coverage

InDex Pharmaceuticals HoldingNeodynamicsBoMill

Latest content

Showing All content types
Analyst Comment

Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.

2023-03-29 by Claus Thestrup
InDex Pharmaceuticals Holding
Analyst Comment

Zerion Pharma: A disruptive solution for poor drug solubility

2023-03-16 by Claus Thestrup
Zerion Pharma
Analyst Comment

NeoDynamics: Management elaborates on options for long-term financing

2023-03-16 by Claus Thestrup
Neodynamics
Analyst Comment

Introduktion til nyt dansk biotekselskab Pharma Equity Group

2023-03-06 by Claus Thestrup
Pharma Equity Group
Analyst Comment

Qlife - Soft-launch of their first CRP biomarker test under the Egoo Health brand

2023-03-04 by Claus Thestrup
Qlife Holding
Analyst Comment

Interview with CEO Magnus Corfitzen from Ascelia Pharma on latest data on the SPARKLE study.

2023-03-03 by Claus Thestrup
Ascelia Pharma
Analyst Comment

BoMill appoints new Head of Sales

2023-03-01 by Claus Thestrup
BoMill
Analyst Comment

NeoDynamics is investigating options to raise long-term capital to enable commercialization of NeoNavia in the US

2023-03-01 by Claus Thestrup
Neodynamics
Analyst Comment

InDex Pharmaceuticals will attend the ECCO 2023 congress

2023-02-28 by Claus Thestrup
InDex Pharmaceuticals Holding
Analyst Comment

Interview with CEO Ulrich Krasilnikoff and CSO Andreas Kjær on highlights from FY 2022 and update on pipeline

2023-02-28 by Claus Thestrup
Curasight
Connecting investors and companies

Our social objective is to democratize information in the financial markets, so that everyone has equal opportunity to invest and save for their own future.

Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Itämerentori 2
    00180 Helsinki
  • About Us
  • Service terms
  • Privacy policy
  • Research disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.